This webinar is designed to enhance laboratory readiness for cancer biomarker testing, with a focused deep dive into immunohistochemistry (IHC). Led by expert pathologists and laboratory professionals, this session will draw on extensive real-world experience to support laboratories in implementing, optimizing, and standardizing IHC protocols for cancer biomarker detection.
Course topics include:
- Assessing laboratory operational readiness for new cancer IHC biomarker assays
- Regulatory and validation requirements for IHC testing
- Strategic implementation decisions
- Analytical performance and quality assurance
- Compliant reporting and pathologist preparedness
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Learning Objectives
Upon completion of this activity, you will be able to:
- Assess laboratory readiness for implementing new cancer IHC biomarker assays
- Analyze operational and financial considerations for IHC implementation
- Differentiate regulatory pathways and validation requirements for IHC assays
- Explain the clinical and regulatory significance of IHC biomarkers in oncology
- Identify resources and strategies to improve laboratory readiness for cancer IHC biomarker testing
Faculty
Georgios Deftereos, MD, FASCP
Professor, Pathology
Associate Director, Clinical Cancer Genomics Laboratory
Director, Molecular Cytopathology
University of California, San Francisco
Karla Valencia, MBA, QIHC, HT(ASCP)
Laboratory Manager
MD Anderson Cancer Center
Houston, Texas
Faculty Disclosures
Karla Valencia and Christopher A. Tormey, MD have no financial relationships to disclose. Georgios Deftereos financial relationships were reviewed and underwent mitigation by a member of the ASCP Commission on Continuing Professional Development.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of 1.0 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of Participation
To complete the activity and receive credit, the participant must participate in the live webinar. CME certificates will be provided online.
Commercial Support
This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.